Original Article
Protective Conditioning for Acute Graft-versus-Host Disease
N Engl J Med 2005; 353:1321-1331September 29, 2005
- Abstract
Background
Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans.
Methods
Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor.
Results
Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy).
Conclusions
A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute GVHD and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation.
Media in This Article
Figure 1
Nonmyeloablative Conditioning Regimen of Total Lymphoid Irradiation and Antithymocyte Globulin.Figure 2
Multilineage Chimerism in Patients Who Underwent Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin.Article Activity
- Article
Allogeneic hematopoietic-cell transplantation with the use of conditioning regimens of nonmyeloablative radiotherapy, chemotherapy, or both to decrease early toxic effects extends the possibility of hematopoietic-cell transplantation to patients older than 50 years and those with coexisting conditions.1-4 However, acute graft-versus-host disease (GVHD) remains a major problem after nonmyeloablative transplantation: acute GVHD (grade II or higher) developed in 20 to 65 percent of the patients in single-center or multicenter trials.5-10 Death due to this complication accounts for approximately 50 percent of the deaths that are not due to a relapse of the neoplasm.3,4,10
A new approach to the prevention of acute GVHD takes advantage of the immune system's regulatory T cells. Two types of regulatory T cell in mice, natural killer T cells and CD4+CD25+ T cells, can prevent acute GVHD.11-14 These regulatory T cells inhibit the proliferation of and cytokine secretion by CD4+ and CD8+ donor T cells that injure the intestines, liver, and skin in acute GVHD.11,14 Nevertheless, direct tumor-killing activity mediated by donor CD8+ T cells remains unaffected.12 Thus, regulatory T cells can separate GVHD from the antitumor activity of the graft. Regulatory natural killer T cells of either donor or host origin have the unique capacity to prevent acute GVHD by secreting interleukin-4.13-15 Natural killer T cells recognize a nonpolymorphic, major-histocompatibility-complex class I–like antigen-presenting molecule, CD1d, which is present on both the donor and host antigen-presenting cells.16
Natural killer T cells constitute only 1 to 3 percent of all T cells in the spleen in normal mice. After repeated treatment with low-dose irradiation targeted to the spleen, thymus, and lymph nodes, however, the proportion of these cells progressively increases until ultimately they constitute the majority of T cells in the spleen and bone marrow.14,15 This change probably results from the resistance of natural killer T cells, as compared with conventional T cells, to radiation-induced apoptosis due to increased expression of antiapoptotic genes by the natural killer T cells.17 In preclinical studies, murine recipients of allogeneic bone marrow that underwent conditioning with anti–T-cell antibodies and repeated low-dose irradiation targeted to the lymphoid tissue (total lymphoid irradiation) were fully protected from GVHD, whereas mice that underwent conditioning with anti–T-cell antibodies and a single dose of total-body irradiation were not protected.14,15 Studies of the pattern of cytokine secretion by donor T cells in protected hosts showed a polarization toward a pattern of type 2 helper T (Th2) cells, with increased secretion of interleukin-4.15 The Th2 cells assist B cells to produce antibodies and reduce the inflammation promoted by type 1 helper T cells.
In the present study, we adapted the conditioning regimen of total lymphoid irradiation that reduces the incidence of acute GVHD in rodents to the treatment of humans with lymphoid malignant diseases or acute leukemia.
Methods
Patients
Beginning on December 28, 2001, 37 consecutive patients were enrolled in a treatment protocol that was reviewed and approved by the Stanford University administrative panel on human subjects in medical research. Observations were carried out through December 1, 2004. Patients were eligible for the study if they had received a diagnosis of lymphoid malignant diseases or acute leukemia, were 50 years of age or older, were younger than 50 years but had preexisting medical conditions, or had received prior therapy and were considered to be at too high a risk for conventional myeloablative transplantation. For patients with lymphoid malignant diseases, no exclusions were made on the basis of disease status, sensitivity to chemotherapy, or prior bacterial or fungal infection. For patients with acute leukemia to be eligible, bone marrow aspirates were required to show less than 5 percent of blasts within six weeks before the start of the conditioning regimen. No patient refused to undergo the experimental conditioning regimen. All patients provided written informed consent. Patients were to be excluded if they were pregnant or if they had decompensated liver disease, a corrected pulmonary-diffusing capacity of less than 35 percent, a cardiac ejection fraction of less than 30 percent, a Karnofsky performance status of less than 50 percent, or serologic evidence of infection with the human immunodeficiency virus.
The Regimen
Total lymphoid irradiation was administered from a 15-MeV linear accelerator (photon beam) at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) had been delivered. The irradiation consisted of a supradiaphragmatic mantle field, a subdiaphragmatic field that included an inverted Y, and splenic ports encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease.18 Antithymocyte globulin (Thymoglobulin, SangStat), at a dose of 1.5 mg per kilogram of body weight per day, was given intravenously on days –11 through –7, with day 0 being the day of transplantation (Figure 1AFigure 1
Nonmyeloablative Conditioning Regimen of Total Lymphoid Irradiation and Antithymocyte Globulin.). All patients received prophylactic medications against bacterial, fungal, and viral infections and were monitored for cytomegalovirus and Epstein–Barr virus with the use of a blood polymerase-chain-reaction assay, as previously described.4,7 Immunosuppressive therapy after transplantation included oral cyclosporine started on day –3, at a dose of 6.25 mg per kilogram twice per day, and mycophenolate mofetil, at a dose of 15 mg per kilogram twice a day, started on the first day after transplantation. Among recipients of matched grafts from related donors, cyclosporine was tapered to discontinuation from day 56 to day 180, and mycophenolate mofetil was stopped on day 28. Among recipients of matched grafts from unrelated donors, cyclosporine was tapered to discontinuation from day 100 to day 180, and mycophenolate mofetil was tapered to discontinuation from day 42 to day 96.Molecular and Serologic Typing
Patients with sibling donors were serologically matched for HLA-A and B antigens and were matched by high-resolution DNA typing for HLA-DRB1 alleles. Patients with unrelated donors were matched for HLA-A, B, and DRB1 alleles with the use of high-resolution (DNA sequencing) molecular typing and for HLA-C and DQB1 alleles with the use of low-resolution molecular typing.
Donor Cells
Related and unrelated donors received a five-day course of subcutaneous granulocyte colony-stimulating factor (at a dose of 16 μg and 10 μg per kilogram of body weight per day, respectively), and mononuclear cells were harvested by leukapheresis. The CD34+ and CD3+ content of cells in the graft was determined according to the standard guidelines of the International Society of Hematotherapy and Graft Engineering.20,21
Assessment of Chimerism and of Antithymocyte Globulin in Serum
The status of hematopoietic chimerism was determined at intervals of one to six months after transplantation by DNA genotyping of simple sequence-length polymorphic markers that encode short tandem repeats, performed by the histocompatibility laboratory at the Stanford Medical School, as previously described in detail.22 The analysis of chimerism was performed on whole blood and on blood mononuclear cells separated into T cells, B cells, and granulocytes with the use of immunomagnetic beads (Dynal) coated with monoclonal antibodies against CD3, CD19, and CD15, respectively. Samples were analyzed at SangStat for the presence of rabbit IgG, with the use of an enzyme-linked immunosorbent assay, and for the fraction of antithymocyte globulin that retained the capacity to bind to human CD3+ T cells (active antithymocyte globulin).19
Control Patients
We studied two groups of control patients. One group of four patients was treated for the myelodysplastic syndrome with hematopoietic-cell transplantation after undergoing conditioning with three doses of fludarabine, at a dose of 30 mg per kilogram, followed by a single dose of total-body irradiation (200 cGy), and the same GVHD and antimicrobial prophylaxis as that received by patients who underwent the experimental conditioning regimen. The other group of five control patients received an allogeneic hematopoietic-cell transplant for the treatment of myeloma after undergoing conditioning with only total-body irradiation (200 cGy), as previously described.7,23
Cytokine Secretion by CD4+ and CD8+ T Cells
Peripheral-blood mononuclear cells from normal control subjects, control patients receiving total-body irradiation, and patients receiving total lymphoid irradiation were stimulated in vitro with phorbol myristate acetate and ionomycin for six hours, with brefeldin A (Sigma-Aldrich) added after two hours.12 The cells were stained with allophycocyanin anti-CD4 monoclonal antibody and with phycoerythrin or fluorescein isothiocyanate anti-CD8 monoclonal antibody and were subsequently permeabilized with the use of a saponin-based reagent (Cytofix-Cytoperm kit, BD Bioscience). After permeabilization, the cells were stained for intracellular cytokines with the use of fluorescein isothiocyanate anti–interleukin-2 monoclonal antibody, phycoerythrin anti–interleukin-4 monoclonal antibody, fluorescein isothiocyanate anti–interferon-γ monoclonal antibody, and fluorescein isothiocyanate-anti–tumor necrosis factor α (TNF-α) monoclonal antibody, in accordance with the manufacturer's instructions. The cells were gated on CD4+ or CD8+ cells and analyzed for the percentage of gated cells that were positive on staining for each cytokine with the use of multicolor flow-cytometric analysis.12
Mixed-Lymphocyte–Reaction Assay
Mononuclear cells from normal control subjects and from patients who had undergone total lymphoid irradiation or total-body irradiation were enriched for CD4+ T cells by incubation with phycoerythrin–anti-CD4 monoclonal antibody, with the use of antiphycoerythrin-conjugated immunomagnetic beads, and the cells were then purified on columns (MACS system, Miltenyi Biotech). The CD4+ cells were more than 90 percent pure, as judged by flow cytometry. These cells were tested for proliferative immune responses to alloantigens in culture for five days in complete medium with irradiated (5000 cGy) stimulator cells made from a pool of mononuclear cells obtained from three normal subjects. The cultures were labeled with 3H-thymidine during the last 20 hours and harvested, and the supernatants were assayed in a scintillation counter.24
Statistical Analysis
Comparisons of the values of the results of laboratory tests of samples obtained from patients in different groups and from normal control subjects were calculated with the use of the Wilcoxon two-sample rank test. Actuarial overall survival and progression-free survival were calculated with the use of a Kaplan–Meier analysis.
Results
Patients' Characteristics
Table 1Table 1
Characteristics of Patients Undergoing Nonmyeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG). summarizes the clinical features of the 37 patients enrolled in the study. Of these, 24 had lymphoid malignant diseases and 13 had acute leukemia. Twenty-eight patients had advanced disease, and 13 of the 24 patients with a lymphoid malignant disease had a relapse after undergoing autologous transplantation.Conditioning Regimen
The total lymphoid irradiation regimen, consisting of 10 doses of lymphoid irradiation of 80 cGy each, was administered over a period of 11 days, and antithymocyte globulin was given on each of the first 5 days (Figure 1A). Patients were admitted to the hospital for the administration of antithymocyte globulin. On completion of the regimen of total lymphoid irradiation, the patients were given an intravenous infusion of granulocyte colony-stimulating factor–mobilized mononuclear cells from HLA-matched related donors (23 patients, 62 percent) or unrelated donors (14 patients, 38 percent). The mean (±SD) absolute numbers of CD34+ hematopoietic progenitor cells and CD3+ T cells in these infusions were 5.8±2.4×106 per kilogram of body weight and 2.4±0.9×108 per kilogram, respectively.
We found that the nonmyeloablative regimen of total lymphoid irradiation and antithymocyte globulin caused only minor neutropenias (Figure 1B). All the patients had persistent lymphopenia, with a marked reduction in CD4+ helper T cells, after transplantation (Figure 1C). Despite the lymphopenia, antithymocyte globulin that bound to lymphocytes (as judged with the use of immunofluorescent staining) was not detected in the recipients' serum after day 7 (Figure 1D). There were too few circulating host T cells at the time of transplantation to determine whether an increase in host natural killer T cells had occurred, as observed in the rodent spleen and bone marrow.14,15
Multilineage donor hematopoietic-cell engraftment, including T cells, B cells, and granulocytes, was uniformly achieved within 56 days after transplantation (Figure 2AFigure 2
Multilineage Chimerism in Patients Who Underwent Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin.). However, the donor T cells subsequently declined in number and were markedly reduced or undetectable within 75 to 200 days after transplantation in 6 of the 37 patients (Figure 2B). The decline in the number of donor B cells and granulocytes was similar to that for the donor T cells (data not shown). In four of these six patients, the loss of donor cells occurred during tumor progression or relapse.Acute GVHD
All patients were monitored after transplantation for the principal manifestations of acute GVHD — diarrhea, rash, and abnormal results on liver-function tests. Standard scores for GVHD on a scale from grade 0 through grade IV were used during the first 100 days after transplantation to diagnose acute GVHD,25 and thereafter, patients were evaluated for chronic GVHD, which was classified as absent, limited, or extensive.26,27
Among the 24 patients with lymphoid malignant diseases (of whom 13 received a transplant from a sibling and 11 from an unrelated donor), acute GVHD was scored as grade 0 in 22 patients, grade I in 1 patient, and grade III in 1 patient (Table 2Table 2
Outcomes among the 24 Patients with Lymphoid Malignant Diseases.). GVHD in this last patient responded to corticosteroids. Among the 13 patients with acute leukemia (of whom 10 received a graft from a sibling and 3 from an unrelated donor), acute GVHD was scored as grade 0 in all patients (Table 3Table 3
Outcomes among the 13 Patients with Acute Leukemia.).Twenty patients with lymphoid malignant diseases survived for more than 100 days and were evaluated for the development of chronic GVHD. Among these patients, 14 had no evidence of chronic GVHD, 2 had limited chronic GVHD, and 4 had extensive chronic GVHD (Table 2). All 13 patients with acute leukemia survived for more than 100 days; 10 had no evidence of chronic GVHD, and 3 had extensive chronic GVHD (Table 3).
Survival and Tumor Response
Among transplant recipients with lymphoid malignant diseases, the follow-up for the first enrolled patient was 1069 days, and for the last enrolled patient it was 222 days; the median follow-up among the surviving patients was 482 days (Table 2). For the 13 patients with acute leukemia, the period of follow-up for the first patient enrolled and the last patient enrolled was 215 and 1041 days, respectively, and the median follow-up of surviving patients was 446 days (Table 3).
Of the 24 patients with lymphoid malignant diseases, 17 (71 percent) survived, all with a Karnofsky performance status score of 100 percent (indicating normal daily functioning) (Table 2).28 Of the 13 patients with acute leukemia, 10 (77 percent) survived, all of them with a performance status of 90 percent or more (Table 3). For patients who died, the causes of death are given in the footnotes to Table 2 and Table 3.
Only 4 of the 24 patients who received a transplant as treatment for lymphoid malignant diseases were in complete remission when the regimen of total lymphoid irradiation and antithymocyte globulin was started. Eighteen of these 24 patients had evidence of residual disease (partial remission) on clinical examination or on computed tomography, positron-emission tomography, or both, and two patients had progressive disease (Table 2). Of the four patients in complete remission at the time of transplantation, three were still in complete remission at the last follow-up visit and the fourth had a relapse. Of the 18 patients with measurable disease at the start of the conditioning regimen, 12 had complete remission without detectable acute GVHD. All patients whose condition changed from partial to complete remission were in complete remission at the last follow-up visit. Four of 18 patients who had partial remission at the start of the conditioning regimen of total lymphoid irradiation and antithymocyte globulin still had evidence of disease at the last observation; of these 4 patients, 2 had disease progression. The two remaining patients who had partial remission at the time of transplantation died from causes other than relapse within six months after transplantation, and for that reason their disease status could not be ascertained by tumor imaging. However, autopsy revealed microscopical tumor foci in one patient (Patient 7).
All 13 patients with acute leukemia were in the first or a subsequent complete remission before starting the conditioning regimen. Remission status was assigned on the basis of histologic analysis of samples of bone marrow obtained six weeks before the start of the regimen. Of these 13 patients, 9 had a first complete remission and 4 had two or four remissions. Of the nine who had a first complete remission, seven continued to be in complete remission and two had a relapse. Of the four who underwent transplantation while in a second or fourth complete remission, one continued to have a complete remission and three had a relapse. Among the patients with lymphoid malignant diseases, the actuarial overall survival and progression-free survival rates were 62 percent and 55 percent, respectively; among the patients with acute leukemia, the actuarial overall survival and progression-free survival rates were 73 percent and 69 percent, respectively.
Severe Infections
Four patients were hospitalized because of viral infection, fungal infection, or both: one patient had a gastrointestinal cytomegalovirus infection, one had a fungal pneumonitis, and two had multidermatomal herpes zoster or multifocal herpes simplex virus type 1 infection. These four patients and an additional five patients also had bacterial infections. All viral, bacterial, and fungal infections were controlled with the use of antimicrobial therapy, with the exception of one fatal case of bacteremia. In total, 28 of the 37 patients had no evidence of any clinically significant infection.
Function of CD4+ T Cells
We obtained purified mononuclear cells from the blood of the transplant recipients within one to seven months after transplantation and stimulated these cells in vitro with phorbol myristate acetate and ionomycin. The stimulated cells were analyzed for the accumulation in the CD4+ and CD8+ T cells of interferon-γ, interleukin-4, interleukin-2, and TNF-α with the use of immunofluorescent staining and flow cytometry. As shown in Figure 3AFigure 3
Comparison of Intracellular Cytokine Production and the Proliferation of CD4+ and CD8+ T Cells., the mean percentages of CD4+ and CD8+ cells that expressed intracellular interferon-γ, interleukin-2, or TNF-α did not differ significantly among the patients who had undergone total lymphoid irradiation, the normal controls, and the control patients who had received transplants and had undergone conditioning with low-dose total-body irradiation (P=0.13 to 0.94 for interferon-γ, P=0.06 to 0.90 for interleukin-2, and P=0.14 to 0.90 for TNF-α, as calculated with the Wilcoxon rank test). Control patients who had received transplants were those without acute GVHD. In contrast, among patients who had undergone total lymphoid irradiation, the mean percentage of CD4+ T cells that expressed interleukin-4 was significantly higher than among the normal controls (P=0.04 by the Wilcoxon rank test) or among control subjects who had undergone total-body irradiation with or without fludarabine (P=0.05 by the Wilcoxon rank test); the mean percentage of interleukin-4–positive CD4+ cells in the total-lymphoid-irradiation group was about five times that in the control groups.We compared the mixed-lymphocyte reaction of purified CD4+ T cells obtained from the normal controls and from the transplant recipients who had full chimerism and had undergone conditioning with either total lymphoid irradiation and antithymocyte globulin or low-dose total-body irradiation (Figure 3B). Although there was no significant difference in the means between the group of normal controls and the group of patients who had undergone total-body irradiation (P=1.0), the mean value for patients who had undergone total lymphoid irradiation was significantly reduced, as compared with normal controls and with patients who had undergone total-body irradiation (P=0.03 for both comparisons by the Wilcoxon rank test).
Discussion
In our study, the incidence of acute GVHD, grades II through IV, among recipients of hematopoietic-cell transplants who had undergone a conditioning regimen of total lymphoid irradiation plus antithymocyte globulin (1 of 37 patients, 3 percent) was markedly lower than that reported in studies of nonmyeloablative conditioning with total-body irradiation, chemotherapeutic agents, or both, conducted by researchers at our institution or elsewhere.1-10 This reduction in the incidence of acute GVHD is especially noteworthy because 14 of the 37 patients received transplants from unrelated donors. In previous studies of recipients of hematopoietic-cell transplants from unrelated donors, the incidence of acute GVHD grades II through IV was more than 50 percent.5-7,9,10
In addition to the low incidence of acute GVHD among the transplant patients, 12 of 16 patients with lymphoid malignant diseases who entered the study while in partial remission and who were evaluated for tumor status after transplantation were in complete remission. The contributions of the conditioning regimen of total lymphoid irradiation and of the antitumor activity of the graft to these changes are difficult to distinguish from each other, except in seven patients who had clearing of the tumor outside the field of the total lymphoid irradiation. Of the 17 patients who entered the study in complete remission, 12 continued to have complete remission, with a median follow-up of 425 days.
In preclinical studies, the protection afforded against GVHD by the conditioning regimen of total lymphoid irradiation plus antithymocyte globulin in wild-type host mice was dependent on host natural killer T cells, since protection was lost in mice in which the CD1d gene was inactivated, causing developmental failure of natural killer T cells in the thymus and other lymphoid tissue.15 After the wild-type mice were treated with total lymphoid irradiation, the natural killer T cells were the main source of host interleukin-4, which subsequently increased the production of interleukin-4 by donor T cells.14,15 In the current study, we were unable to measure directly the number and function of host natural killer T cells, because assays were limited to the blood samples obtained immediately after the patients underwent the conditioning regimen, and these samples contained too few host T cells for testing. Subsequently, we enrolled seven additional patients, and by increasing the volume of the blood samples obtained from each of the patients, we were able to measure the percentage of natural killer T cells in five of these patients. The median percentage of natural killer T cells among all T cells was increased by a factor of 10 after the patients underwent the experimental conditioning regimen, owing to a more profound decrease in the absolute number of non–natural killer T cells than of natural killer T cells (data not shown).
After the patients underwent transplantation, we found a marked increase in the production of interleukin-4 by donor CD4+ T cells in the transplant recipients, as compared with interleukin-4 production by CD4+ T cells in the normal control subjects, as was observed in mice.15 These donor CD4+ T cells also showed a marked reduction in their proliferative response to alloantigenic stimulation in the mixed-lymphocyte reaction. Donor CD4+ T cells from patients who underwent conditioning with total-body irradiation, rather than total lymphoid irradiation plus antithymocyte globulin, showed neither an increased production of interleukin-4 nor a reduced proliferative response.
Although we could not distinguish the separate contributions of total lymphoid irradiation and antithymocyte globulin to protection against GVHD, preclinical studies have shown that the combination of total-body irradiation and antithymocyte globulin fails to provide protection against GVHD.14,15 It is likely that the changes in the function of donor T cells in the patients who underwent total lymphoid irradiation reduced the risk of acute GVHD, since donor T cells with a profile of increased Th2 cytokine secretion have a decreased capacity to induce GVHD in rodents.29-31
In conclusion, a regimen of nonmyeloablative conditioning of total lymphoid irradiation plus antithymocyte globulin given before hematopoietic-cell transplantation for lymphoid malignant diseases or acute leukemia can markedly decrease the incidence of acute GVHD while retaining the antitumor effect of the graft.
Supported in part by the National Institutes of Health (grants P01-CA49605, P01-HL-075462, P01-HL-57443, RO1-HL-58250, and RO1-AI-37683) and by a Faculty Scholar Award from the American Society of Hematology (to Dr. Lowsky).
We are indebted to Dr. Kartoosh Heydari for data on natural killer T cells in blood samples obtained from seven patients outside this study; to Dr. Tyson Holmes for the graphic display of data on T-cell chimerism for all patients; and to Aditi Mukhopadhyay for assistance in the acquisition and processing of blood samples.
Source Information
From the Departments of Medicine (R.L., T.T., Y.P.L., S.D.-J., J.A.S., G.G.L., K.E.S.-G., L.J.J., K.G.B., R.S.N., S.S.), Pathology (F.C.G.), Radiation Oncology (R.T.H.), and Health Research and Policy (D.A.B.), Stanford University School of Medicine, Stanford, Calif.
Address reprint requests to Dr. Strober at the Center for Clinical Sciences Research Building, Rm. 2215, 269 W. Campus Dr., Stanford, CA 94305-5290.
- References
References
1
Slavin S ,Nagler A ,Naparstek E , et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763
Web of Science | Medline2
Childs R ,Clave E ,Contentin N , et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241
Web of Science | Medline3
Giralt S ,Thall PF ,Khouri I , et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637
CrossRef | Web of Science | Medline4
McSweeney PA ,Niederwieser D ,Shizuru JA , et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400
CrossRef | Web of Science | Medline5
Maris MB ,Sandmaier BM ,Storer BE , et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542
CrossRef | Web of Science | Medline6
Georges GE ,Maris M ,Sandmaier BM , et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol 2002;76:Suppl 1:184-189
CrossRef | Web of Science | Medline7
Niederwieser D ,Maris M ,Shizuru JA , et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;15:1620-1629
CrossRef | Web of Science8
Mielcarek M ,Martin PJ ,Leisenring W , et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762
CrossRef | Web of Science | Medline9
Schetelig J ,Kroger N ,Held TK , et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002;87:299-305
Web of Science | Medline10
Spitzer TR ,MaAfee S ,Sackstein R , et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309-320
CrossRef | Web of Science | Medline11
Hoffmann P ,Ermann J ,Edinger M ,Fathman CG ,Strober S . Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399
CrossRef | Web of Science | Medline12
Edinger M ,Hoffmann P ,Ermann J , et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-1150
CrossRef | Web of Science | Medline13
Zeng D ,Lewis D ,Dejbakhsh-Jones S , et al. Bone marrow NK1.1- and NK1.1+ T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189:1073-1081
CrossRef | Web of Science | Medline14
Lan F ,Zeng D ,Higuchi M ,Huie P ,Higgins JP ,Strober S . Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: “natural suppressor“ cells. J Immunol 2001;167:2087-2096
Web of Science | Medline15
Lan F ,Zeng D ,Higuchi M ,Higgins JP ,Strober S . Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003;9:355-363
CrossRef | Web of Science | Medline16
Bendelac A ,Lantz O ,Quimby ME ,Yewdell JW ,Bennink JR ,Brutkiewicz RR . CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-865
CrossRef | Web of Science | Medline17
Seino K ,Harada M ,Taniguchi M . NKT cells are relatively resistant to apoptosis. Trends Immunol 2004;25:219-221
CrossRef | Web of Science | Medline18
Kaplan HS ,Rosenberg SA . Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. Cancer Res 1966;26:1268-1276
Web of Science | Medline19
Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, US Thymoglobulin Multi-Center Study Group
CrossRef | Web of Science | Medline20
Sutherland DR ,Anderson L ,Keeney M ,Nayar R ,Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996;5:213-226
CrossRef | Medline21
1997 Revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR Recomm Rep 1997;46:1-29
22
Millan MT ,Shizuru JA ,Hoffmann P , et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002;73:1386-1391
CrossRef | Web of Science | Medline23
Maloney DG ,Molina AJ ,Sahebi F , et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454
CrossRef | Web of Science | Medline24
Strober S ,Benike C ,Krishnaswamy S ,Engleman EG ,Grumet FC . Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation 2000;69:1549-1554
CrossRef | Web of Science | Medline25
Glucksberg H ,Storb R ,Fefer A , et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304
CrossRef | Web of Science | Medline26
Sullivan KM ,Agura E ,Anasetti C , et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259
Web of Science | Medline27
Przepiorka D ,Weisdorf D ,Martin P , et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828
Web of Science | Medline28
Karnofsky DA ,Abelman WH ,Craver LC ,Burcherd JH . The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634-656
CrossRef | Web of Science29
Fowler DH ,Kurasawa K ,Smith R ,Eckhaus MA ,Gress RE . Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994;84:3540-3549
Web of Science | Medline30
Fowler DH ,Kurasawa K ,Husebekk A ,Cohen PA ,Gress RE . Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction: regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994;152:1004-1013
Web of Science | Medline31
Pan L ,Delmonte J Jr ,Jalonen CK ,Ferrara JLM . Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-4429
Web of Science | Medline
- Citing Articles (114)
Citing Articles
1
E. Krystufkova, A. Sekerkova, I. Striz, I. Brabcova, E. Girmanova, O. Viklicky. (2011) Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrology Dialysis Transplantation
CrossRef2
A. C. Logan, H. Gao, C. Wang, B. Sahaf, C. D. Jones, E. L. Marshall, I. Buno, R. Armstrong, A. Z. Fire, K. I. Weinberg, M. Mindrinos, J. L. Zehnder, S. D. Boyd, W. Xiao, R. W. Davis, D. B. Miklos. (2011) High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proceedings of the National Academy of Sciences
CrossRef3
Diana Stauch, Ali Yahyazadeh, Roberta Bova, Götz-Christian Melloh, Arne Füldner, Udo Baron, Sven Olek, Katrin Göldner, Sascha Weiss, Johann Pratschke, Katja Kotsch. (2011) Induction of bona fide regulatory T cells after liver transplantation - the potential influence of polyclonal antithymocyte globulin. Transplant Internationalno-no
CrossRef4
K.-H. Lee, J.-H. Lee, J.-H. Lee, D.-Y. Kim, M. Seol, Y.-S. Lee, Y.-A. Kang, M. Jeon, H.-J. Hwang, A.-R. Jung, S.-H. Kim, S.-C. Yun, H.-J. Shin. (2011) Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 118:9, 2609-2617
CrossRef5
Robert S. Negrin. (2011) Role of regulatory T cell populations in controlling graft vs host disease. Best Practice & Research Clinical Haematology 24:3, 453-457
CrossRef6
Mark A. Exley, Lydia Lynch, Bindu Varghese, Michael Nowak, Nadia Alatrakchi, Steven P. Balk. (2011) Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects. Clinical Immunology 140:2, 184-195
CrossRef7
Samuel Strober, Thomas R. Spitzer, Robert Lowsky, Megan Sykes. (2011) Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction. Seminars in Immunology 23:4, 273-281
CrossRef8
Asha Pillai, Christine Hartford, Chong Wang, Deqing Pei, Jie Yang, Ashok Srinivasan, Brandon Triplett, Mari Dallas, Wing Leung. (2011) Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatric Transplantationno-no
CrossRef9
Kyoo-Hyung Lee, Seong-Jun Choi, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Sung-Cheol Yun, Young-Don Joo, Won-Sik Lee, Myoung-Joo Kang, Hawk Kim, Jae-Hoo Park, Sung-Hwa Bae, Hun-Mo Ryoo, Min-Kyoung Kim, Myung-Soo Hyun. (2011) Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. American Journal of Hematology 86:5, 399-405
CrossRef10
Joanna M. Schaenman, Sumana Shashidhar, Chanu Rhee, Jonathan Wong, Shelly Navato, Ruby M. Wong, Dora Y. Ho, Sally Arai, Laura Johnston, Janice M. Brown. (2011) Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. Biology of Blood and Marrow Transplantation 17:5, 693-702
CrossRef11
C E Hill-Kayser, J P Plastaras, Z Tochner, E Glatstein. (2011) TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplantation 46:4, 475-484
CrossRef12
D. B. Leveson-Gower, J. A. Olson, E. I. Sega, R. H. Luong, J. Baker, R. Zeiser, R. S. Negrin. (2011) Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood 117:11, 3220-3229
CrossRef13
Akiko Yamane, Takehiko Mori, Jun Kato, Yukako Ono, Shinichiro Okamoto. (2011) Discrepancy in the kinetics of total and active anti-thymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation. International Journal of Hematology 93:3, 406-407
CrossRef14
D Tseng, C D Jones, M Anderson, R Warnke, J L Zehnder, D B Miklos. (2011) Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. Bone Marrow Transplantation
CrossRef15
Ya-Jen Chang, Hye Young Kim, Lee A. Albacker, Hyun Hee Lee, Nicole Baumgarth, Shizuo Akira, Paul B. Savage, Shin Endo, Takashi Yamamura, Janneke Maaskant, Naoki Kitano, Abel Singh, Apoorva Bhatt, Gurdyal S. Besra, Peter van den Elzen, Ben Appelmelk, Richard W. Franck, Guangwu Chen, Rosemarie H. DeKruyff, Michio Shimamura, Petr Illarionov, Dale T. Umetsu. (2011) Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. Journal of Clinical Investigation 121:1, 57-69
CrossRef16
Vanessa Morales-Tirado, Wioleta Luszczek, Marié van der Merwe, Asha Pillai. (2011) Regulatory Immunotherapy in Bone Marrow Transplantation. TheScientificWorldJOURNAL 11, 2620-2634
CrossRef17
Carol D. Jones, Sally Arai, Robert Lowsky, Dolly B. Tyan, James L. Zehnder, David B. Miklos. (2010) Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. British Journal of Haematology 150:5, 637-639
CrossRef18
Francesca DʼAddio, Xueli Yuan, Antje Habicht, John Williams, Melanie Ruzek, John Iacomini, Laurence A. Turka, Mohamed H. Sayegh, Nader Najafian, M. Javeed Ansari. (2010) A Novel Clinically Relevant Approach to Tip the Balance Toward Regulation in Stringent Transplant Model. Transplantation 90:3, 260-269
CrossRef19
S Patil, A Spencer, A Schwarer, I Lewis, M Hertzberg, S Avery, A Wei, T Noutsos, E Paul, Y Taouk, J Muirhead. (2010) Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. Bone Marrow Transplantation 45:7, 1154-1160
CrossRef20
Holbrook E. Kohrt, Asha B. Pillai, Robert Lowsky, Samuel Strober. (2010) NKT cells, Treg, and their interactions in bone marrow transplantation. European Journal of Immunology 40:7, 1862-1869
CrossRef21
Mohamad Mohty, Beatrice Gaugler. (2010) Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. Best Practice & Research Clinical Haematology 23:2, 275-282
CrossRef22
Steven C Goldstein, David L Porter. (2010) Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Expert Review of Hematology 3:3, 301-314
CrossRef23
A. Osama Gaber, Anthony P. Monaco, James A. Russell, Yvon Lebranchu, Mohamad Mohty. (2010) Rabbit Antithymocyte Globulin (Thymoglobulin®). Drugs 70:6, 691-732
CrossRef24
S. D. Boyd, E. L. Marshall, J. D. Merker, J. M. Maniar, L. N. Zhang, B. Sahaf, C. D. Jones, B. B. Simen, B. Hanczaruk, K. D. Nguyen, K. C. Nadeau, M. Egholm, D. B. Miklos, J. L. Zehnder, A. Z. Fire. (2009) Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing. Science Translational Medicine 1:12, 12ra23-12ra23
CrossRef25
R. Broady, J. Yu, M. K. Levings. (2009) ATG-induced expression of FOXP3 in human CD4+ T cells in vitro is associated with T-cell activation and not the induction of FOXP3+ T regulatory cells. Blood 114:24, 5003-5006
CrossRef26
Luis M. Villela, Javier Bolaños-Meade. (2009) Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. Clinical Cancer Reviews 3:1, E14-E24
CrossRef27
Andrea Bacigalupo, Karen Ballen, Doug Rizzo, Sergio Giralt, Hillard Lazarus, Vincent Ho, Jane Apperley, Shimon Slavin, Marcelo Pasquini, Brenda M. Sandmaier, John Barrett, Didier Blaise, Robert Lowski, Mary Horowitz. (2009) Defining the Intensity of Conditioning Regimens: Working Definitions. Biology of Blood and Marrow Transplantation 15:12, 1628-1633
CrossRef28
G. Socie, B. R. Blazar. (2009) Acute graft-versus-host disease: from the bench to the bedside. Blood 114:20, 4327-4336
CrossRef29
Holbrook Kohrt, Robert Lowsky. (2009) Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Current Opinion in Hematology 16:6, 460-465
CrossRef30
Tsuyoshi Takahashi, Mineo Kurokawa. (2009) Human invariant natural killer T cells: implications for immunotherapy. International Journal of Hematology 90:2, 137-142
CrossRef31
Josep M. Cruzado, Oriol Bestard, Josep M. Grinyó. (2009) New Immunosuppressive Protocols With the Advent of Novel Biological Drugs. Transplantation 88:Supplement, S20-S23
CrossRef32
Peggy A. Wu, Youn H. Kim, Phillip W. Lavori, Richard T. Hoppe, Keith E. Stockerl-Goldstein. (2009) A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Biology of Blood and Marrow Transplantation 15:8, 982-990
CrossRef33
Shoshana Morecki, Shimon Slavin. (2009) Immunoregulation of GVHD by triggering the innate immune system with CpG. Expert Review of Hematology 2:4, 443-453
CrossRef34
H. E. Kohrt, B. B. Turnbull, K. Heydari, J. A. Shizuru, G. G. Laport, D. B. Miklos, L. J. Johnston, S. Arai, W.-K. Weng, R. T. Hoppe, P. W. Lavori, K. G. Blume, R. S. Negrin, S. Strober, R. Lowsky. (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114:5, 1099-1109
CrossRef35
Holbrook Kohrt, Robert Lowsky. (2009) Total lymphoid irradiation for graft-versus-host disease protection. Current Opinion in Oncology 21:Suppl 1, S23-S26
CrossRef36
Francis Ayuk, Axel Zander, Nicolaus Kröger. (2009) Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma. Annals of Hematology 88:5, 401-404
CrossRef37
James LM Ferrara, John E Levine, Pavan Reddy, Ernst Holler. (2009) Graft-versus-host disease. The Lancet 373:9674, 1550-1561
CrossRef38
A. B. Pillai, T. I. George, S. Dutt, S. Strober. (2009) Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 113:18, 4458-4467
CrossRef39
B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, P. Bavaro, F. Onida, A. Busca, L. Castagna, E. Benedetti, A. P. Iori, L. Giaccone, A. Palumbo, P. Corradini, R. Fanin, D. Maloney, R. Storb, I. Baldi, U. Ricardi, M. Boccadoro. (2009) Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 113:14, 3375-3382
CrossRef40
Benedetto Bruno, Luisa Giaccone, Roberto Sorasio, Mario Boccadoro. (2009) Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Seminars in Hematology 46:2, 158-165
CrossRef41
Gina LaCorcia, Mark Swistak, Carla Lawendowski, Su Duan, Tim Weeden, Sharon Nahill, John M. Williams, John L. Dzuris. (2009) Polyclonal Rabbit Antithymocyte Globulin Exhibits Consistent Immunosuppressive Capabilities Beyond Cell Depletion. Transplantation 87:7, 966-974
CrossRef42
Zhenyu Yao, Yinping Liu, Jennifer Jones, Samuel Strober. (2009) Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4 + Bcl-2 hi NKT cells. European Journal of Immunology 39:3, 763-775
CrossRef43
Takeshi Yamashita, Chiharu Sugimori, Ken Ishiyama, Hirohito Yamazaki, Hirokazu Okumura, Yukio Kondo, Akiyoshi Takami, Shinji Nakao. (2009) Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. International Journal of Hematology 89:2, 238-242
CrossRef44
Megan Sykes. (2009) Hematopoietic Cell Transplantation for Tolerance Induction: Animal Models to Clinical Trials. Transplantation 87:3, 309-316
CrossRef45
Kyoo-Hyung Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Se-Hyung Kim, Ho-Jin Shin, Young-Shin Lee, Young-Ah Kang, Miee Seol, Sung-Gil Ryu. (2009) Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor Is Feasible Without Ex Vivo-T Cell Depletion after Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin. Biology of Blood and Marrow Transplantation 15:1, 61-72
CrossRef46
Pavan Reddy, Mukta Arora, Martin Guimond, Crystal L. Mackall. (2009) GVHD: A Continuing Barrier to the Safety of Allogeneic Transplantation. Biology of Blood and Marrow Transplantation 15:1, 162-168
CrossRef47
Shin-ichiro FUJII. (2009) Immunological evaluation for CML and its possibility for an immunotherapy. Japanese Journal of Clinical Immunology 32:4, 231-241
CrossRef48
Kyoo-Hyung Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim. (2009) Allogeneic Hematopoietic Cell Transplantation from an HLA-mismatched Family Donor: The Current Status and Future. Journal of the Korean Medical Association 52:8, 819
CrossRef49
Vijay K. Sharma, Utpal K. Singh, Rajniti Prasad, Sophie Fletcher. (2009) Stem Cell Through Present and Future. The Indian Journal of Pediatrics 76:1, 51-56
CrossRef50
A Toor, T Rodriguez, M Bauml, H Mathews, S Shanti, D Senitzer, A Kini, J Norton, M Parthasarathy, N Mohideen, C Petrowsky, B Bonilla, S Smith, P Stiff. (2008) Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. Bone Marrow Transplantation 42:11, 723-731
CrossRef51
Thomas Fehr, Megan Sykes. (2008) Clinical experience with mixed chimerism to induce transplantation tolerance. Transplant International 21:12, 1118-1135
CrossRef52
Lakshmanan Krishnamurti, Sandhya Kharbanda, Melinda A. Biernacki, Wandi Zhang, K. Scott Baker, John E. Wagner, Catherine J. Wu. (2008) Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation 14:11, 1270-1278
CrossRef53
I. L. Weissman, J. A. Shizuru. (2008) The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112:9, 3543-3553
CrossRef54
John Koreth, Joseph H Antin. (2008) Current and future approaches for control of graft-versus-host disease. Expert Review of Hematology 1:1, 111-128
CrossRef55
Minghui Li, Kai Sun, Lisbeth A Welniak, William J Murphy. (2008) Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opinion on Pharmacotherapy 9:13, 2305-2316
CrossRef56
Francis A. Ayuk, Nabil Atassi, Gunther Schuch, Sormeh Mina, Lubin Fang, Carsten Bokemeyer, Boris Fehse, Axel R. Zander, Nicolaus Kröger. (2008) Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leukemia Research 32:8, 1200-1206
CrossRef57
Laura Johnston. (2008) Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Practice & Research Clinical Haematology 21:2, 177-192
CrossRef58
Tomomi Toubai, Yaping Sun, Pavan Reddy. (2008) GVHD pathophysiology: is acute different from chronic?. Best Practice & Research Clinical Haematology 21:2, 101-117
CrossRef59
C Messina, M Faraci, V de Fazio, G Dini, M P Calò, E Calore. (2008) Prevention and treatment of acute GvHD. Bone Marrow Transplantation 41, S65-S70
CrossRef60
Lazaros Lekakis, Marcos de Lima. (2008) Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Expert Review of Anticancer Therapy 8:5, 785-798
CrossRef61
Jan Storek. (2008) Immunological reconstitution after hematopoietic cell transplantation – its relation to the contents of the graft. Expert Opinion on Biological Therapy 8:5, 583-597
CrossRef62
X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, N. S. Young. (2008) Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 111:7, 3675-3683
CrossRef63
Angela Shaulov, Simon Yue, RuoJie Wang, Robin M. Joyce, Steven P. Balk, Haesook T. Kim, David E. Avigan, Lynne Uhl, Robert Sackstein, Mark A. Exley. (2008) Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival. Experimental Hematology 36:4, 464-472
CrossRef64
A. Beilhack, S. Schulz, J. Baker, G. F. Beilhack, R. Nishimura, E. M. Baker, G. Landan, E. I. Herman, E. C. Butcher, C. H. Contag, R. S. Negrin. (2008) Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 111:5, 2919-2928
CrossRef65
Yin Ping Liu, Zengqi Li, Roland G. Nador, Samuel Strober. (2008) Simultaneous Protection Against Allograft Rejection and Graft-Versus-Host Disease After Total Lymphoid Irradiation: Role of Natural Killer T Cells. Transplantation 85:4, 607-614
CrossRef66
Frank Heinzelmann, Peter J. Lang, Hellmut Ottinger, Christoph Faul, Wolfgang Bethge, Rupert Handgretinger, Michael Bamberg, Claus Belka. (2008) Immunosuppressive Total Lymphoid Irradiation-Based Reconditioning Regimens Enable Engraftment After Graft Rejection or Graft Failure in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation. International Journal of Radiation Oncology*Biology*Physics 70:2, 523-528
CrossRef67
Scandling, John D., Busque, Stephan, Dejbakhsh-Jones, Sussan, Benike, Claudia, Millan, Maria T., Shizuru, Judith A., Hoppe, Richard T., Lowsky, Robert, Engleman, Edgar G., Strober, Samuel, . (2008) Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation. New England Journal of Medicine 358:4, 362-368
Full Text68
Samuel Strober. (2008) Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Blood Cells, Molecules, and Diseases 40:1, 48-54
CrossRef69
Mohamad Mohty, Béatrice Gaugler. (2008) Mechanisms of action of antithymocyte globulin: old dogs with new tricks!. Leukemia & Lymphoma 49:9, 1664-1667
CrossRef70
Michael T. Lotze, Markus Y. Mapara, Carl H. June. 2008. Tumor immunology and immunotherapy. , 1181-1195.
CrossRef71
Yoshihiro Inamoto, Ritsuro Suzuki, Yachiyo Kuwatsuka, Takahiko Yasuda, Taro Takahashi, Akane Tsujimura, Kyoko Sugimoto, Taku Oba, Seitaro Terakura, Yoshiko Atsuta, Makoto Murata, Masafumi Ito, Yoshihisa Kodera, Koichi Miyamura. (2008) Long-Term Outcome after Bone Marrow Transplantation for Aplastic Anemia Using Cyclophosphamide and Total Lymphoid Irradiation as Conditioning Regimen. Biology of Blood and Marrow Transplantation 14:1, 43-49
CrossRef72
Kenneth Brayman. (2007) New Insights Into the Mechanisms of Action of Thymoglobulin. Transplantation 84:Supplement, S3-S4
CrossRef73
M. Mohty. (2007) Allogreffe de cellules souches hématopoïétiques avec conditionnement à intensité réduite: situation en 2007 et perspectives. Oncologie 9:12, 842-847
CrossRef74
Robert Lowsky. (2007) Thymoglobulin and Regulatory T Cells in Organ and Hematopoietic Cell Transplantation. Transplantation 84:Supplement, S20-S26
CrossRef75
James L.M. Ferrara, Claudio Anasetti, Edward Stadtmauer, Joseph Antin, John Wingard, Stephanie Lee, John Levine, Kirk Schultz, Frederick Appelbaum, Robert Negrin, Sergio Giralt, Christopher Bredeson, Helen Heslop, Mary Horowitz. (2007) Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biology of Blood and Marrow Transplantation 13:11, 1268-1285
CrossRef76
Olaf Penack, Lars Fischer, Chiara Gentilini, Axel Nogai, Arne Muessig, Kathrin Rieger, Susanne Ganepola, Eckhard Thiel, Lutz Uharek. (2007) The type of ATG matters — Natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transplant Immunology 18:2, 85-87
CrossRef77
Yaping Sun, Isao Tawara, Tomomi Toubai, Pavan Reddy. (2007) Pathophysiology of acute graft-versus-host disease: recent advances. Translational Research 150:4, 197-214
CrossRef78
Tom V. Adamkiewicz, Paul Szabolcs, Ann Haight, K. Scott Baker, Susan Staba, Amos Kedar, K. Y. Chiang, Lakshmanan Krishnamurti, Michael W. Boyer, Joan Kurtzberg, John E. Wagner, John R. Wingard, Andrew M. Yeager. (2007) Unrelated cord blood transplantation in children with sickle cell disease: Review of four-center experience. Pediatric Transplantation 11:6, 641-644
CrossRef79
M. Sykes. (2007) Immune tolerance: mechanisms and application in clinical transplantation. Journal of Internal Medicine 262:3, 288-310
CrossRef80
David M Hockenbery. (2007) Oral beclomethasone dipropionate in gastrointestinal graft-versus-host disease. Expert Review of Clinical Immunology 3:5, 695-700
CrossRef81
D. T. Chung, T. Korn, J. Richard, M. Ruzek, A. P. Kohm, S. Miller, S. Nahill, M. Oukka. (2007) Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. International Immunology 19:8, 1003-1010
CrossRef82
Ben Sprangers, Bart Van Wijmeersch, Sabine Fevery, Mark Waer, An D Billiau. (2007) Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nature Clinical Practice Oncology 4:7, 404-414
CrossRef83
M Mohty. (2007) Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21:7, 1387-1394
CrossRef84
(2007) Allografting or Autografting for Myeloma. New England Journal of Medicine 356:25, 2646-2648
Full Text85
Robert E. Cirocco, Manuel R. Carre??o, James M. Mathew, Rolando O. Garcia-Morales, Laphalle Fuller, Violet Esquenazi, Gaetano Ciancio, George W. Burke, Jeffrey J. Gaynor, Bonnie B. Blomberg, Anne Rosen, Gary Kleiner, Camillo Ricordi, Joshua Miller. (2007) FoxP3 mRNA Transcripts and Regulatory Cells in Renal Transplant Recipients 10 Years After Donor Marrow Infusion. Transplantation 83:12, 1611-1619
CrossRef86
Warren D. Shlomchik. (2007) Graft-versus-host disease. Nature Reviews Immunology 7:5, 340-352
CrossRef87
Issa F. Khouri, Rima M. Saliba, Joan Admirand, Susan O'Brien, Ming-S. Lee, Martin Korbling, Barry I. Samuels, Sergio Giralt, de Marcos Lima, Michael J. Keating, Richard E. Champlin, Carlos Bueso-Ramos. (2007) Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. British Journal of Haematology 137:4, 355-363
CrossRef88
Andrea Bacigalupo. (2007) Management of acute graft-versus-host disease. British Journal of Haematology 137:2, 87-98
CrossRef89
Bruno, Benedetto, Rotta, Marcello, Patriarca, Francesca, Mordini, Nicola, Allione, Bernardino, Carnevale-Schianca, Fabrizio, Giaccone, Luisa, Sorasio, Roberto, Omedè, Paola, Baldi, Ileana, Bringhen, Sara, Massaia, Massimo, Aglietta, Massimo, Levis, Alessandro, Gallamini, Andrea, Fanin, Renato, Palumbo, Antonio, Storb, Rainer, Ciccone, Giovannino, Boccadoro, Mario, . (2007) A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. New England Journal of Medicine 356:11, 1110-1120
Full Text90
Mark H. Kirschbaum. (2007) Lessons of war: Progress in transplant conditioning regimens. Leukemia & Lymphoma 48:12, 2300-2301
CrossRef91
Dale T. Umetsu, Everett H. Meyer, Rosemarie H. DeKruyff. (2007) Natural Killer T Cells Regulate the Development of Asthma. International Reviews of Immunology 26:1-2, 121-140
CrossRef92
J. H. Antin. (2007) Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. Hematology 2007:1, 47-54
CrossRef93
Robert S. Negrin, Jing-Zhou Hou. (2007) Promise and Challenges of Human Regulatory T Cells in the Clinic. Biology of Blood and Marrow Transplantation 13, 12-16
CrossRef94
Chad R. Gordon, Chau Y. Tai, Hidetoshi Suzuki, Louise F. Strande, Rajendra Ramsamooj, Martha S. Matthews, Kirby S. Black, Charles W. Hewitt. (2007) Review of vascularized bone marrow transplantation: Current status and future clinical applications. Microsurgery 27:4, 348-353
CrossRef95
Dale T. Umetsu, Rosemarie H. DeKruyff. (2006) A role for natural killer T cells in asthma. Nature Reviews Immunology 6:12, 953-958
CrossRef96
David L. Porter, Joseph H. Antin. (2006) Donor leukocyte infusions in myeloid malignancies: new strategies. Best Practice & Research Clinical Haematology 19:4, 737-755
CrossRef97
J SCHAFFER. (2006) The Changing Face of Graft-Versus-Host Disease. Seminars in Cutaneous Medicine and Surgery 25:4, 190-200
CrossRef98
A Kikuta, M Ito, K Mochizuki, M Akaihata, K Nemoto, H Sano, H Ohto. (2006) Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplantation 38:10, 665-669
CrossRef99
Daniel H. Fowler, Jeanne Odom, Seth M. Steinberg, Catherine K. Chow, Jason Foley, Yelena Kogan, Jeannie Hou, Juan Gea-Banacloche, Claude Sportes, Steven Pavletic, Susan Leitman, Elizabeth J. Read, Charles Carter, Arne Kolstad, Rebecca Fox, Gregory L. Beatty, Robert H. Vonderheide, Bruce L. Levine, Carl H. June, Ronald E. Gress, Michael R. Bishop. (2006) Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4+ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 12:11, 1150-1160
CrossRef100
H M Lazarus, J M Rowe. (2006) Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 20:10, 1673-1682
CrossRef101
H J Deeg, M B Maris, B L Scott, E H Warren. (2006) Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 20:10, 1701-1705
CrossRef102
Anastasios Karadimitris, Scott Patterson, Emmanouil Spanoudakis. (2006) Natural killer T cells and haemopoiesis. British Journal of Haematology 134:3, 263-272
CrossRef103
Dale T. Umetsu, Rosemarie H. DeKruyff. (2006) The regulation of allergy and asthma. Immunological Reviews 212:1, 238-255
CrossRef104
Lisa Y. Law, Sandra J. Horning, Ruby M. Wong, Laura J. Johnston, Ginna G. Laport, Robert Lowsky, Judith A. Shizuru, Karl G. Blume, Robert S. Negrin, Keith E. Stockerl-Goldstein. (2006) High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 12:7, 703-711
CrossRef105
Robert S. Negrin, Christopher H. Contag. (2006) In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nature Reviews Immunology 6:6, 484-490
CrossRef106
Margrit Wiesendanger, Anfisa Stanevsky, Susan Kovsky, Betty Diamond. (2006) Novel therapeutics for systemic lupus erythematosus. Current Opinion in Rheumatology 18:3, 227-235
CrossRef107
Copelan, Edward A., . (2006) Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine 354:17, 1813-1826
Full Text108
Robert Lowsky, Robert S Negrin. (2006) Total lymphoid irradiation and transplantation tolerance. Current Opinion in Organ Transplantation 11:1, 54-61
CrossRef109
Alexandra King. (2006) Novel nonmyeloablative conditioning regimen protects against GVHD. Nature Clinical Practice Oncology 3:1, 9-9
CrossRef110
Krishna V. Komanduri, Daniel Couriel, Richard E. Champlin. (2006) Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation: Evolving Concepts and Novel Therapies Including Photopheresis. Biology of Blood and Marrow Transplantation 12:1, 1-6
CrossRef111
(2005) Protective Conditioning for Acute Graft-versus-Host Disease. New England Journal of Medicine 353:25, 2718-2718
Full Text112
Megan Sykes, Thomas R Spitzer. (2005) Protecting the host naturally. Nature Medicine 11:11, 1164-1165
CrossRef113
&NA;. (2005) Nonmyeloablative conditioning reduces post-transplant GVHD. Inpharma Weekly &NA;:1508, 17
CrossRef114
Socié, Gérard, . (2005) Graft-versus-Host Disease — From the Bench to the Bedside?. New England Journal of Medicine 353:13, 1396-1397
Full Text
- Letters
